Ardian Targets 2011 For First Launch Of RF Catheter That Treats Hypertension
This article was originally published in The Gray Sheet
Executive Summary
Ardian plans to introduce the first catheter-based treatment for uncontrolled hypertension in Europe by 2011 and in the U.S. by 2013
You may also be interested in...
Randomized Trials Underway For Renal Denervation To Treat Hypertension
Ardian is moving forward with a prospective randomized clinical trial to study its Symplicity radiofrequency catheter for ablation of the sympathetic renal nerves to treat chronic hypertension, following successful results of its first-in-man study
Randomized Trials Underway For Renal Denervation To Treat Hypertension
Ardian is moving forward with a prospective randomized clinical trial to study its Symplicity radiofrequency catheter for ablation of the sympathetic renal nerves to treat chronic hypertension, following successful results of its first-in-man study
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009
Highlights from the Q1 2009 review of medical device and in vitro diagnostics/research dealmaking. Device financing activity remained down bringing in only $522 million--the majority invested through VCs, mostly via late-stage venture rounds--not much change from the previous quarter, but a significant drop from Q1 2008, which saw $920 million. Device M&A brought in $4.4 billion, double the previous quarter, but most of Q1's money came from Abbott's $2.86 billion purchase of Advanced Medical Optics. Four other transactions topped the $200 million mark, including three deals by device giant Medtronic, which grabbed cardio companies CoreValve, Ventor Technologies, and Ablation Frontiers. There was also a decline in in vitro diagnostics and research fund-raising with 2009's opening quarter only seeing about half the dollars of Q4 2008.